News coverage about Tabula Rasa HealthCare (NASDAQ:TRHC) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tabula Rasa HealthCare earned a news sentiment score of 0.04 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.5017061625933 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Tabula Rasa HealthCare (NASDAQ:TRHC) traded down $1.70 during midday trading on Wednesday, hitting $34.89. 434,700 shares of the stock were exchanged, compared to its average volume of 228,355. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.66 and a current ratio of 0.73. The stock has a market cap of $653.09, a P/E ratio of -139.56, a PEG ratio of 3.82 and a beta of 3.93. Tabula Rasa HealthCare has a 12-month low of $11.59 and a 12-month high of $39.81.
TRHC has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 10th. Piper Jaffray Companies restated a “buy” rating and set a $29.00 price objective on shares of Tabula Rasa HealthCare in a research note on Tuesday, October 24th. BidaskClub lowered shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research note on Friday, December 15th. Citigroup initiated coverage on shares of Tabula Rasa HealthCare in a research note on Thursday, January 4th. They set a “buy” rating for the company. Finally, Oppenheimer initiated coverage on shares of Tabula Rasa HealthCare in a research note on Monday, December 18th. They set an “outperform” rating and a $35.00 price objective for the company. Three research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Tabula Rasa HealthCare has an average rating of “Buy” and a consensus price target of $29.78.
WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Tabula Rasa HealthCare (TRHC) Stock Price” was first reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-tabula-rasa-healthcare-trhc-stock-price/1896900.html.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.